Atlas of Staging in Gynecological Cancer by J. Richard Smith, Guiseppe Del Priore, & Jeremiah Healy Hardcover - 150 pages Shipped in CLICK HERE Cat.# DA-ONC17 $122.70 BUY Published:  2008   ISBN:  9781846284335

• Difficult areas within each chapter are summarised reinforcing the central points and key message of each chapter
• Describes the two common staging regimes used by all units across the world, namely, the FIGO staging system and the TNM system
• Unique landscape format allows each chapter to open on the left hand side and read across the double spread, enabling the reader to see both staging systems at once

'Atlas of Staging in Gynecological Cancer' is designed to be used in conjunction with diagnostic procedures between the surgeon and the radiologist. It describes the two common staging regimes used by all units across the world, namely, the FIGO staging system and the TNM system.

The ‘landscape’ format allows each chapter to open on the left hand side and read across the double spread, enabling the reader to see both staging systems at once. Each chapter has a separate section on Epidemiology, Diagnosis, with radiological plates, Management, in tabular form, and Key Points. The book takes the reader through each gynaecologic cancer with a short text accompanying clear radiographic images with legends. Staging is also shown in pictorial form in order to aid clarity.

The book will be of particular interest to the multi-disciplinary team who looks after this group of patients namely, clinical and radiation oncologists, surgeons, pathologists, radiologists and specialist nurses, all with their respective trainees.

Contents:
Introduction. Cervical cancer. Vaginal cancer. Vulval carcinoma. Endometrial cancer. Ovarian cancer. Gestational trophoblastic disease.

Prostate Cancer Signaling Networks, Genetics, and New Treatment Strategies Edited by Richard G. Pestell, and Marja T. Nevalainen Hardcover - 430 pages Shipped in CLICK HERE Cat.# DA-ONC20 $200.85 BUY Published:  2008   ISBN:  9781588297419

• Comprehensive, with up-to-date reviews on all aspects of biology and treatment of prostate cancer
• Translational resource for clinicians and researchers
• Discusses recent advances in prostate cancer treatment
• Provides insight into future, novel treatment strategies

Award winning authors present a comprehensive review of new perspectives in prostate cancer research and open up new directions in the clinical management of prostate cancer. In, "Prostate Cancer: Signaling Networks, Genetics, and New Treatment Strategies", the authors focus on the biology, genetics, molecular signaling networks in the disease process, and recent advances in the treatment of prostate cancer. This state-of-the-art title provides key insights into cutting edge advances in prostate cancer research, such as laparoscopic radical prostatectomy, and offers a critical evaluation and discussion of opportunities for development of novel therapies for prostate cancer.

Clinical trials that have not been covered or evaluated in any other books currently available are also discussed. Invaluable to physicians and researchers, "Prostate Cancer: Signaling Networks, Genetics, and New Treatment Strategies" provides a comprehensive translational resource as well as an important source of information for prostate cancer patients.

Contents:
Histopathology and Molecular Biology of Prostate Atrophy: A Lesion Associated with Inflammation, PIN, and Prostate Cancer. Epigenetic Gene Silencing in Prostate Cancer. Inherited Genetic Changes in Prostate Cancer. Prostate Molecular Oncogenesis: Gene Deletions and Somatic Mutations. Somatic Genetic Changes in Prostate Cancer: Androgen Receptor Alterations. Androgen Receptor in Prostate Cancer Progression. Epigenetic Modification and Acetylation of Androgen Receptor Regulate Prostate Cellular Growth. Estrogen Receptor Alpha and Beta in the Regulation of Normal and Malignant Prostate Epithelium. Estrogen Action in Normal Prostate Epithelium and in Prostate Cancer. Hypoxia Inducible Factor 1 and Angiogenesis in Prostate Cancer. Signal Transduction by the Ras – MAP Kinase Pathway in Prostate Cancer Progression. Transcription Factors Stat5 and Stat3: Survival Factors for Prostate Cancer Cells. Role of PI3K-Akt and PTEN in the Growth and Progression of Prostate Cancer. New Perspectives in Prediction of Clinical Outcome of Prostate Cancer: TMPRSS2-ETS Gene Fusion in Prostate Cancer. New Directions in Radiation Therapy of Prostate Cancer: Brachytherapy and Intensity Modulated Radiation Therapy. Advances in Surgical Intervention of Prostate Cancer: Comparison of the Benefits and Pitfalls of Retropubic, Perineal and Laparoscopic Radical Prostatectomy. Targeted Therapy Trials for Prostate Cancer. New Perspectives on Chemotherapy of Prostate Cancer. Concluding Remarks: The Future of Prostate Cancer.

Lung Cancer Edited by Jack A. Roth, James D. Cox, and Waun Ki Hong Hardcover - 480 pages Shipped in CLICK HERE Cat.# JW-ONC15 $186.35 BUY Published:  2008   ISBN:  9781405151122

Lung cancer is a major cause of cancer-related deaths in men and women. However, since the first edition of Lung Cancer was published 14 years ago, rapid progress in the biology, prevention, diagnosis, and treatment of the disease has been made.

Table of Contents:

Contributors
Preface

1. Smoking Cessation
2. Lung Cancer Susceptibility Genes
3. Lung Cancer Susceptibility and Risk Assessment Models
4. The Molecular Genetics of Lung Cancer
5. Molecular Biology of Preneoplastic Lesions of the Lung
6. Detection of Preneoplastic Lesions
7. Treatment of Preneoplastic Lesions of the Lung
8. The Pathology and Pathogenesis of Peripheral Lung Adenocarcinoma Including Bronchioloalveolar Carcinoma
9. Treatment of Bronchioloalveolar Carcinoma
10. Molecular Profiling for Early Detection and Prediction of Response in Lung Cancer
11. The Role for Mediastinoscopy in the Staging of Nonsmall Cell Lung Cancer
12. Minimally Invasive Surgery for Lung Cancer
13. Extended Resections for Lung Cancer
14. Adjuvant Chemotherapy Following Surgery for Lung Cancer
15. Induction Chemotherapy for Resectable Lung Cancer
16. Image-Guided Radiation Therapy
17. Stereotactic Body Radiation Therapy for Lung Cancer
18. Proton Therapy
19. Combinations of Radiation Therapy and Chemotherapy for Nonsmall Cell Lung Carcinoma
20. New Chemotherapeutic Agents in Lung Cancer
21. Immunologic Approaches to Lung Cancer Therapy
22. Epidermal Growth Factor Receptor Inhibitors
23. Tumor Angiogenesis: Biology and Therapeutic Implications for Lung Cancer
24. Retinoids and Rexinoids in Lung Cancer Prevention and Treatment
25. Proteasome Inhibition in Nonsmall Cell Lung Cancer Therapy
26. Targeted Genetic Therapy for Lung Cancer
27. Screening for Early Detection
28. Natural Agents for Chemoprevention of Lung Cancer

Vladimir Badmaev (Sabinsa Pharmaceutical, Inc., New Jersey), Burton Dickey (The University of Texas M.D. Anderson Cancer Center), and Jonathan Kurie (The University of Texas M.D. Anderson Cancer Center).

Index

Viral Therapy of Cancer by K. J. Harrington, Richard G. Vile, and Hardev Pandha Hardcover - 432 pages Shipped in CLICK HERE Cat.# JW-ONC16 $171.80 BUY Published:  2008   ISBN:  9780470019221

This book provides an in-depth analysis of the current status of all the key viruses that are being developed as treatments for cancer. It is the first book to describe the use of viruses as oncolytic agents, killing cells directly, and it bridges the gap between bench research and clinical applications.

Viral Therapy of Cancer reviews all aspects of viral applications in the treatment of cancer, including quality, control and regulatory issues in various countries. Edited by three experts in the field of cancer gene therapy with experience in both laboratory and clinical research, this book is an invaluable resource for both basic scientists and clinicians with an interest in virology and gene therapy.

Table of Contents:

Foreword
Preface

1. Adenoviruses

1.1 Introduction
1.2 Viral structure and lifecycle
1.3 Adenoviral vectors
1.4 Targeting adenoviral vectors
1.5 Clinical applications of adenoviral gene therapy
1.6 Adenoviral vectors for immunotherapy
1.7 Adenoviral vectors for suicide gene therapy
1.8 Adenoviral vectors for gene replacement therapy
1.9 Oncolytic adenoviral therapy
1.10 Adverse outcomes of adenoviral gene therapy
1.11 Summary

References

2. Application of HSV-1 factors to the treatment of cancer

2.1 Introduction
2.2 Basic biology of HSV
2.3 Replication competent or oncolytic vectors
2.4 Replication defective vectors
2.5 Amplicons
2.6 Impediments to the efficacy of HSV vectors for cancer gene therapy
2.7 Strategies to enhance the efficacy and specificity of HSV vectors for cancer gene therapy
2.8 Summary and conclusions

References

3. Adeno-associated virus

3.1 Introduction
3.2 Biology and life cycle of AAV
3.3 AAV serotypes
3.4 Production of recombinant AAV
3.5 Gene therapy for cancer treatment
3.6 Anti-oncogenic properties of AAV
3.7 Molecular chemotherapy studies with rAAV
3.8 AAV-mediated sustained transgene expression as a potential cancer gene therapy strategy
3.9 rAAV vectors have advantages in stimulating T helper 1/cytotoxic T lymphocyte responses
3.10 rAAV vectors can be used to initiate immune responses
3.11 Altering AAV tropism for tumour-specific delivery
3.12 Clinical trials involving rAAV
3.13 Conclusion

Acknowledgements
References

4. Retroviruses

4.1 Introduction
4.2 Structure of retroviral particles
4.3 Retroviral genome
4.4 Retroviral life cycle
4.5 Retroviral vectors
4.6 Safety of retroviral vectors: insertional mutagenesis
4.7 Gene therapy of X-linked SCID
4.8 Retroviral cancer gene therapy
4.9 Immunomodulatory approaches
4.10 Conclusions

References

5. Lentiviral vectors for cancer gene therapy

5.1 Development of lentiviral vectors (LV)
5.2 Targeting of transgene expression
5.3 Host immune responses to LV and their transgene
5.4 Transgenesis
5.5 Haematopoietic stem cell gene transfer
5.6 Cancer treatment by LV
5.7 Approved clinical trials using LV
5.8 Conclusions

References

6. Poxviruses as immunomodulatory cancer therapeutics

6.1 Introduction
6.2 General features of poxvirus structure and biology
6.3 Clinically applicable poxviruses
6.4 Poxviruses as potential cancer therapeutics
6.5 Clinical experience with poxviruses
6.6 Conclusion

References

7. Oncolytic herpes simplex viruses

7.1 Introduction
7.2 Herpes simplex virology
7.3 Properties of HSV relevant to oncolytic virus therapy
7.4 Mutations giving tumour-selective replication
7.5 Oncolytic HSV expressing fusogenic membrane glycoproteins (FMG)
7.6 Prodrug activation therapy and oncolytic HSV
7.7 Combination of oncolytic HSV with immunomodulatory gene expression
7.8 Combination of conventional therapies with oncolytic HSV
7.9 Summary

Acknowledgement
References

8. Selective tumour cell cytotoxicity by reoviridae - preclinical evidence and clinical trial results

8.1 Introduction
8.2 Reovirus structure
8.3 Reovirus replication
8.4 Reovirus and human infection
8.5 Oncolytic activitiy
8.6 Mechanism of reovirus-induced cytotoxicity
8.7 Preclinical experience
8.8 Immunogeneicity
8.9 Clinical experience
8.10 Conclusions

References

9. Oncolytic vaccinia

9.1 Introduction
9.2 Biology of vaccinia virus
9.3 Tumour selectivity and antitumour effect
9.4 Improving antitumour effects through bystander effects
9.5 Immune response to vaccinia and vaccinia immune evasion strategies
9.6 Virus-driven antitumour immune response
9.7 Imaging
9.8 Current and potential clinical applications

References

10. Newcastle Disease virus: a promising vector for viral therapy of cancer

10.1 Introduction
10.2 Structure, taxonomy, pathogenicity and oncolytic properties of NDV
10.3 Human application and safety
10.4 Tumour-selective replication of NDV
10.5 Virally based cancer immunotherapy and danger signals
10.6 NDV: a danger signal inducing vector
10.7 The human cancer vaccine ATV-NDV
10.8 Pre-existing antitumour memory T cells from cancer patients and their activation by antitumour vaccination with ATV-NDV
10.9 Clinical trials of antitumour vaccination with ATV-NDV
10.10 NDV-specific recombinant bispecific antibodies to augment anti-tumour immune responses
10.11 NDV-binding bispecific fusion proteins to improve cancer specific virus targeting
10.12 Recombinant NDV as a new vector for vaccination and gene therapy
10.13 Conclusion

References

11. Vesicular stomatitis virus

11.1 Introduction
11.2 Vesicular stomatitis virus (VSV): genomic organization and life cycle
11.3 Host range and pathogenesis of VSV infection
11.4 Control of VSV infection by the innate type I interferon response
11.5 cancer cells are insensitive to type I interferon
11.6 VSV preferentially replicates in and lyses tumour cells in vitro
11.7 VSV attenuation: enhanced tumour selectivity and therapeutic index
11.8 Engineered/recombinant VSV
11.9 VSV effectively eradicates tumours in vivo
11.10 VSV and the host immune response
11.11 Host immunity vs. therapeutic efficacy
11.12 VSV is a potent vaccine
11.13 Innate sensing of VSV and the antitumour response
11.14 So what is a good oncolytic virus?
11.15 Future challenges for VSV

References

12. Measles as an oncolytic virus

12.1 Introduction
12.2 Measles virus and the consequences of natural infection
12.3 MV vaccine
12.4 MV genetics and engineering
12.5 MV receptors
12.6 Animal models for the study of MV pathogenesis and oncolysis
12.7 Oncolytic activity of MV
12.8 Mechanism of specificity
12.9 Targeting MV entry
12.10 Enhancing the oncolytic activity of MV
12.11 Interactions with the immune system
12.12 Potential specific toxicities of clinical use of replicating attenuated MV
12.13 Clinical trials
12.14 Conclusions

References

13. Alphaviruses

13.1 Introduction
13.2 RNA viruses as gene expression vectors
13.3 The biology of alphaviruses
13.4 Heterologous gene expression using alphavirus vectors
13.5 Cancer gene therapy strategies using alphavirus vectors
13.6 Alphavirus vector development for gene therapy application
13.7 Conclusions

References

14. Tumour-suppressor gene therapy

14.1 Tumour-suppressor genes
14.2 Use of tumour-suppressing genes for cancer therapy
14.3 Clinical trials of p53 gene replacement
14.4 Tumour-suppressor gene therapy in multimodality anticancer treatment
14.5 Future prospects

Acknowledgements
References

15. RNA interference and dominant negative approaches

15.1 Introduction
15.2 Oligonucleotide agents
15.3 Mechanism of RNAi
15.4 RNAi and antisense compared
15.5 siRNA design
15.6 Off-target effects
15.7 Induction of innate immunity
15.8 Methods of delivery
15.9 Antisense
15.10 Dominant negative approaches
15.11 Research applications of siRNA
15.12 Therapeutic applications of siRNA

References

16. Gene-directed enzyme prodrug therapy

16.1 Introduction
16.2 Enzyme-prodrug systems for GDEPT
16.3 Gene delivery vectors for GDEPT
16.4 Conclusions

References

17. Immunomodulatory gene therapy

17.1 Introduction
17.2 Immunotherapy strategies using viral vectors
17.3 Viruses used as viral vectors in cancer immunotherapy
17.4 Clinical trials against specific TAA
17.5 Conclusions and future prospects

References

18. Antiangiogenic gene delivery

18.1 Angiogenesis: role in tumour development and metastasis
18.2 Targeting tumour vasculature as an approach for cancer treatment
18.3 Viral vectors to deliver antiangiogenic gene products
18.4 Viral targeting
18.5 Concluding remarks

References

19. Radiosensitization in viral gene therapy

19.1 Introduction
19.2 Adenovirus
19.3 Adeno-associated viruses
19.4 Herpes simplex viruses
19.5 Enhancing the effect of radiation by delivering tumour suppressor genes
19.5 Virus-directed enzyme prodrug therapy
19.6 Conclusion

References

20. Radioisotope delivery

20.1 Introduction
20.2 History of iodine therapy
20.3 Genetic therapy
20.4 Conclusion

References

21. Radioprotective gene therapy: current status and future goals

21.1 Introduction
21.2 Organ-specific radiation protection: oral cavity/oropharynx
21.3 A potential beneficial added observation of antitumour effect of radiation protection using MnSOD-PL
21.4 HA-MnSOD effects on reducing the repopulation (cytoprotective response) induced by irradiation in tumours and the role of EGFR-TKI
21.5 MnSOD-PL treatment to ameliorate the dose limiting oesophageal toxicity of irradiation
21.6 MnSOD-PL treatment reduces pulmonary irradiation damage
21.7 MnSOD-PL systemic administration for radiation protection from TBI
21.8 Summary and future directions

References

22. Chemoprotective gene delivery

22.1 Introduction
22.2 The promise of chemoselection strategies
22.4 The limitations of chemoselection strategies
22.5 Which expression level of chemoprotective genes is appropriate?
22.6 Vector design to achieve optimal expression levels
22.7 Exploring side effects of continued transgene expression and insufficient chemoprotection
22.8 The future: inducible expression of drug resistance genes

Acknowledgements
References

Gastrointestinal Oncology, A Critical Multidisciplinary Approach by Janusz Jankowski, Richard E. Sampliner, MD, David J. Kerr, Yuman Fong, Ernest Hawk, Jaye L. Viner Hardcover - 752 pages Shipped in CLICK HERE Cat.# JW-ONC17 $357.25 BUY Published:  2008   ISBN:  9781405127837

This is the first evidence-based reference text written for the multidisciplinary team of medical professionals involved in the investigation, diagnosis and management of patients with gastrointestinal cancer.

Written by the leading international experts in the field, it sets the standard in clinical practice. It contains specially structured clinical chapters each representing a different role in the MDT - which enables clear presentation and quick reference of the contents.

Table of Contents:

1. Epidemiology of Gastroesophageal Cancer
2. Factors involved in Carcinogenesis and Prevention
3. Molecular Biology of Gastroesophageal Cancers: the Role of Mutational Analysis
4. MDT Approach to Esophageal Adenocarcinoma
5. Squamous Cancer of the Esophagus
6. Diffuse Gastric Cancer
7. Intestinal Gastric Cancer
8. Small Bowel Adenocarcinoma
9. MDT Approach to Sarcoma and Gastrointestinal Stromal Tumors
10. Rare Tumors of the Abdomen
11. Epidemiology and prevention of colorectal cancer
12. Molecular Biology
13. Screening for colorectal cancer
14. Approach to cancer of the colon and rectum
15. Approach to rare tumours/rare cancers of the colon
16. Epidemiology and Molecular Epidemiology
17. Factors involved in Carcinogenesis and Prevention
18. Molecular Biology
19. Approach to Primary Liver Cancer (Hepatoma)
20. Approach to Metastatic Liver Cancer
21. Approach to Primary Pancreatic Adenocarcinoma
22. Approach to Cholangiocarcinoma
23. GI Neuroendocrine Tumors
24. Approach to the Rare Tumors of the Liver
25. Approach to Cystic lesions of the pancreas

Index

Cancer in Children and Young People by Faith Gibson, and Louise Soanes Hardcover - 432 pages Shipped in CLICK HERE Cat.# JW-ONC18 $ 83.60 BUY Published:  2008   ISBN:  9780470058671

Much has changed since the first book Paediatric Oncology: Acute Nursing Care (1999), therefore, this new edition encompasses these changes in relation to the practice itself and the evidence that underpins it. Emphasis is placed on ensuring terminology is accurate, in keeping with the language of the current day.

The book is divided into six sections: Chemotherapy, Haematopoetic Stem Cell Transplantation, General Surgery, Radiotherapy, Late Effects of cancer therapies, and Palliative Care. There is a brief commentary at the end of each section/chapter by a ‘novice’ author but experienced practitioner, highlighting to the reader what is already known and what the section/chapter adds to their current knowledge and practice.

Table of Contents:

Chapter 1: Principles of chemotherapy
Chapter 2: Chemotherapy agents
Chapter 3: Administration of chemotherapy
Chapter 4: Side effects of chemotherapy and supportive
Chapter 5: Oncological emergencies
Chapter 6: Future trends
Commentary: Chemotherapy section.

Section 2: Haematopoetic Stem Cell Transplantation

Chapter 7: Background to HSCT procedure
Chapter 8: Preparation for bone marrow transplant
Chapter 9: Collection and infusion of bone marrow, peripheral blood stem cells and umbilical cord blood
Chapter 10: Protective isolation nursing issues
Chapter 11: Complications of stem cell transplant
Chapter 12: Discharge planning and the psychological care of the family
Chapter 13: Staff support in stem cell transplant units

Chapter 14: Further developments in stem cell transplant
Commentary: Haematopoetic Stem Cell Transplantation

Section 3: Surgery

Chapter 15: General surgery
Commentary: General surgery

Chapter 16: Neuro-oncology
Commentary: Neuro-oncology

Chapter 17: Primary bone cancer in young people
Commentary: Primary bone cancer in young people

Section 4: Radiotherapy

Chapter 18: The nature of radiotherapy
Chapter 19: Administration of radiotherapy
Chapter 20: Tumours and radiotherapy treatment
Chapter 21: Acute and sub-acute side effects of radiotherapy
Chapter 22: The role of radiotherapy and palliative care

Section 5: Late effects of cancer therapies

Chapter 23: Overview of long-term follow-up
Chapter 24: Potential physical issues following cancer treatment
Chapter 25: The role of the nurse in Long-Term Follow-Up
Chapter 26: Health promotion for Long-Term Follow-Up patients
Chapter 27: Quality of Life in long-term survivors of childhood cancer

ABC of Skin Cancer by Sajjad Rajpar, and Jerry Marsden Softcover - 80 pages Shipped in CLICK HERE Cat.# JW-ONC19 $ 46.30 BUY Published:  2008   ISBN:  9781405162197

The ABC of Skin Cancer is designed to boost GP confidence in the diagnosis and referral of skin cancer, focusing on differential diagnosis and common pitfalls. In line with the latest NICE guidelines in the UK, this book outlines best practice management in primary care, whilst also covering the Australian perspective on this cancer. Chapters on non-surgical treatment and prevention are also included.

This new highly illustrated title in the successful ABC series provides a concise, factual and practical overview of skin cancers and pre-cancerous lesions for general practitioners, junior doctors and medical students.

Table of Contents:

1. Epidemiology, aetiology and prevention of melanoma
2. Epidemiology, aetiology and prevention of non-melanoma skin cancer
3. The role of the primary care team in the management of patients with skin cancer
4. Pre-cancerous skin lesions
5. Squamous cell carcinoma
6. Basal cell carcinoma
7. Differential diagnosis of non-melanoma skin cancer
8. Benign pigmented lesions
9. Melanoma – clinical features and diagnosis
10. Melanoma – management and prognosis
11. Surgical treatment of skin cancer
12. Non-surgical treatment of skin cancer
13. Skin cancer – an Australian perspective
14. Rare skin cancers and cutaneous metastases

Skin Cancer by Robert A. Schwartz Hardcover - 536 pages Shipped in CLICK HERE Cat.# JW-ONC20 $212.70 BUY Published:  2008   ISBN:  9781405159616

The second edition of Skin Cancer: Recognition and Management is a definitive clinical reference which comprehensively examines the wide range of premalignant and malignant cutaneous disorders, including melanoma, Kaposi's sarcoma and other sarcomas, cutaneous lymphoma, cutaneous metastatic disease and cutaneous markers of internal malignancy, with emphasis on the most recent advances in diagnosis and management.

Fully revised and expanded, this new edition now includes full colour photographs and illustrations throughout to aid recognition and diagnosis, and covers the latest developments and treatment modalities. New chapters include:

• Merkel Cell Carcinoma
• Dermoscopy

Skin Cancer: Recognition and Management is a definitive clinical reference for dermatologists, oncologists, residents and any medical practitioner with an interest in skin cancer.

Table of Contents:

Contributors
Preface

1. Introduction
2. Actinic keratosis
3. Other premalignant cutaneous dysplasias
4. Bowen’s disease
5. Squamous cell carcinoma
6. Keratoacanthoma
7. Basal cell carcinoma
8. Appendageal carcinomas and cutaneous sarcomas
9. Kaposi’s sarcoma
10. Dysplastic nevus and dysplastic nevus syndrome
11. Melanoma
12. Dermoscopy for skin cancer
13. Merkel cell carcinoma
14. Dermatitic precursors of mycosis fungoides
15. Cutaneous lymphoma, leukemia, and related disorders
16. Cutaneous metastatic disease
17. Cutaneous markers of internal malignancy
18. Early oral and oropharyngeal cancer diagnosis and management
19. Histopathologic considerations in the management of skin cancer
20. Historical survey: methods used to treat skin cancer
21. Curettage and electrodesiccation
22. Cryosurgery
23. Excision of skin cancer
24. Local flap closure in the management of skin cancer
25. The role of skin grafts in the management of skin malignancies
26. Mohs micrographic surgery
27. Photodynamic therapy
28. Cutaneous cancer and radiotherapy
29. Local chemotherapy
30. Topical immunotherapy
31. Treatment of melanoma